Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Arcutis Biotherapeutics Inc.’s current trading price is -69.68% away from its 52-week high, while its distance from the 52-week low is -6.32%. The stock’s price range during this period has varied between $8.87 and $27.40. The company, active in the Healthcare sector, saw a trading volume of around 1.19 million for the day, considerably higher average daily volume of 1.19 million observed over the last three months.
Arcutis Biotherapeutics Inc. (ARQT) has a current stock price of $8.31. During the previous trading session, the stock witnessed a notable rise, reaching a high of $9.39 after opening at $9.39. The stock’s low for the day was $8.87, and it eventually closed at $8.99.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The stock market performance of Arcutis Biotherapeutics Inc. has been fairly unsteady. Over the last year, the company’s stock hit its highest at $27.40 on 08/31/22, while the lowest price during the same time frame was $8.87, recorded on 05/25/23.
How Financial Performance Impacts Market Capitalization
Arcutis Biotherapeutics Inc. (ARQT) has experienced a quarterly decline of -46.94% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 551.00M and boasts a workforce of 268 employees.
Decoding Analysts’ Ratings for Arcutis Biotherapeutics Inc.
As of right now, 8 analysts are rating Arcutis Biotherapeutics Inc. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 13.66, with a change in price of -6.47. Similarly, Arcutis Biotherapeutics Inc. recorded 1,032,524 in trading volume during the last 100 days, posting a change of -43.72%.
How ARQT’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for ARQT stands at 1.42. Similarly, the long-term debt-to-equity ratio is also 1.42.
ARQT Stock Stochastic Average
As of today, the raw stochastic average of Arcutis Biotherapeutics Inc. over the past 50 days is 3.42%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 3.51%. Additionally, the Stochastic %K and %D values for the company were 3.14% and 4.86%, respectively, over the past 20 days.
ARQT Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price loss of -43.86% this year. Over the last six months, there has been a stronger performance of -54.62%. The price of ARQT leaped by -40.22% during the last 30 days period. For the last 5-days stocks have slided -12.07%.
